

Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: <u>officeofthedirector@pcmc.gov.ph</u> Trunkline: 588-9900 DirectLine: 924-0836 Fax No: 924-0840

INVITATION TO BID

SUPPLY AND DELIVERY OF VARIOUS PHARMACEUTICAL FOR CY 2021 VARIOUS COMMON NON-MEDICAL SUPPLIES CY 2021

1. The Philippine Children's Medical Center (PCMC) through the GAA CY 2021 intends to apply the sum of Forty-Six Million Five Hundred Thirteen Thousand Six Hundred Thirty-Eight Pesos & 51/100) (Php 46,513,638.51) being the Approved Budget for the Contract (ABC) to payments under the following Invitation to Bid. Bids received in excess of the ABC shall be automatically rejected at bid opening.

| IB NO. | ITEM DESCRIPTION | ABC (Php) | Cost of Complete Set of Bidding documents |
|-------------|---|---------------|---|
| IB 2021-025 | Various Pharmaceutical Supplies CY 2021 | 45,162,409.06 | 25,000.00 |
| IB 2021-026 | Various Common Non-Medical Supplies CY 2021 | 1,351,229.45 | 5,000.00 |

2. The Philippine Children's Medical Center (PCMC) now invites bids for the above-mentioned project. Delivery of the Goods is required within Seven (7) calendar days. Bidders should have completed, within the past two (2) years from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II. Instructions to Bidders.

3. Bidding will be conducted through open competitive bidding procedures using a nondiscretionary "pass/fail" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act".

a. Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

4. Prospective Bidders may obtain further information from PCMC and inspect the Bidding Documents at the address given below during office hours.

5. A complete set of Bidding Documents may be acquired by interested Bidders starting November 26, 2020 upon payment of the applicable fee stated above. It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) and the website of PCMC, provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.





6. The Philippine Children's Medical Center will hold a Pre-Bid Conference on December 4, 2020 at 10:00 A.M. through video conferencing via *google meet* which shall be open to prospective bidders.

7. Bids must be duly received by the BAC Secretariat through manual submission on or before **December 16, 2020 9:30 A.M., Guard-on-Duty, 3rd Floor, Procurement Division Area, PCMC Main Building.** Late bids shall not be accepted.

8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 14.

9. Bid opening shall be on **December 16, 2020 10:00 A.M. 3rd Floor, Function Hall, PCMC Main Building**. Bids will be opened in the presence of the Bidders' representatives who choose to attend at the afore-mentioned venue. In compliance to social distancing and to support the government's effort to mitigate, if not contain the transmission of COVID-19, we will strictly allow only one authorized representative per bidder company to enter the venue during opening of bids. Provided further, that said authorized representative shall wear PPE and shall pass the triage areas as required prior entering PCMC Premises.

10. The **Philippine Children's Medical Center (PCMC)** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.

11. For further information, please refer to:

PCMC BAC Secretariat 3rd Floor, Procurement Division PCMC Main Building Quezon Avenue, cor. Agham Road Quezon City Trunkline : 8588-9900 Loc 361 / 355 Fax Number: 924-0870 Email : pcmcbac@gmail.com

12. You may visit the following websites:

For downloading of Bidding Document : <u>www.pcmc.gov.ph</u> www.philgeps.gov.ph

November 25, 2020

MARIA ROSARIO S. CRUZ, MD Chairman, Bids & Awards Committee

IB-2021-025 to 2021-026

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|------------|-----------------|--------------|------------------|--------|--------------|----------------------|---------------------|---|--------------------------------------|---|--|---|
| PROC | CURING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REC | QUIRE | MENT | - | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 1 | 00.9% NaCl 100mL (non DHP fully collapsable close system) | 200 | bag | 62.09 | 12,418.00 | | | | | | | | | | |
| 2 | Acetylcysteine amp 100mg/mL 3mL (IMIV) | 15,000 | amp | 92.40 | 1,386,000.00 | | | | | | | | | | |
| 3 | Acetylcysteine sachet 100mg | 6,000 | scht | 10.00 | 60,000.00 | | | | | | | | | | |
| 4 | Aciclovir susp 200mg/5mL, 50mL/60mL | 50 | bt | 338.00 | 16,900.00 | | | | | | | | | | |
| 5 | Albumin H vl 25% 50mL (IV) | 1,800 | vl/ba g | 2,198.90 | 3,958,020.00 | | | | | | | | | | |
| 6 | Alprostadil 0.5mg/mL ampule | 20 | amp | 5,400.00 | 108,000.00 | | | | | | | | | | |
| 7 | Amikacin Sulf amp/vl 125mg/mL, 2mL (IM,IV) | 3,000 | amp/ vl | 38.66 | 115,980.00 | | | | | | | | | | |
| 8 | Amikacin Sulf amp/vl 250mg/mL, 2mL (IM,IV) | 2,500 | amp/ vl | 35.33 | 88,325.00 | | | | | | | | | | |
| 9 | Amino Acid Crystalline Standard bt 5% 500mL (IV inf) | 1,200 | bt | 425.00 | 510,000.00 | | | | | | | | | | |
| 10 | Amoxicillin Trihyd cap 500mg blister/foil pack | 5,000 | cap | 1.50 | 7,500.00 | | | | | | | | | | |

Page 1 of 14

| | | | | | | PI | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|-------|-----------------|------------|------------------|--------|--------------|----------------------|--------------------|--|--------------------------------------|--|---|--|
| PROC | TURING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REQ | | | | | | | | В | IDDER'S C | | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 COST OF | 12 | 13 UNIT PRICES | 14 SALES AND | 15 TOTAL PRICE |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 11 | Amoxicillin Trihyd susp bt 100mg/mL, 15mL | 500 | bt | 21.30 | 10,650.00 | | | | | | | | | | |
| 12 | Ampicillin Sod vl 500mg (IM,IV) | 12,000 | vl | 12.32 | 147,840.00 | | | | | | | | | | |
| 13 | Ascorbic Acid drp bt 100mg/mL, 15mL | 432 | bt | 18.81 | 8,125.92 | | | | | | | | | | |
| 14 | Ascorbic Acid syr bt 100mg/5mL, 120mL | 3,200 | bt | 31.90 | 102,080.00 | | | | | | | | | | |
| 15 | Ascorbic Acid tab 500mg blister/foil pack | 80,000 | tab | 1.98 | 158,400.00 | | | | | | | | | | |
| 16 | Aspirin tab 80mg blister/foil pack | 4,500 | tab | 0.87 | 3,915.00 | | | | | | | | | | |
| 17 | BCG Vacc FD powd vl 500mcg/mL + 1mL diluent amp | 200 | vl | 460.00 | 92,000.00 | | | | | | | | | | |
| 18 | Beractant 25mg/mL, 4mL vl | 90 | vl | 8,995.00 | 809,550.00 | | | | | | | | | | |
| 19 | Bisacodyl Adult supp 10mg | 400 | supp | 20.88 | 8,352.00 | | | | | | | | | | |
| 20 | Bisacodyl Pedia supp 5mg | 300 | supp | 49.30 | 14,790.00 | | | | | | | | | | |

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|---|--------|-------|-----------------|--------------|------------------|--------|--------------|----------------------|---------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF BI | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REG | QUIRE | MENT | - | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 21 | Bisacodyl tab 5mg blister/foil pack | 300 | tab | 3.55 | 1,065.00 | | | | | | | | | | |
| 22 | Bleomycin Sulf powd vl 15units (IM, IV, SC) | 150 | vl | 1,750.00 | 262,500.00 | | | | | | | | | | |
| 23 | Butamirate Citrate tab 50mg MR blister/foil pack | 200 | tab | 14.30 | 2,860.00 | | | | | | | | | | |
| 24 | Calcitriol cap 0.25mcg blister/foil pack | 7,000 | cap | 26.00 | 182,000.00 | | | | | | | | | | |
| 25 | Calcium Carbonate tablet/chewable 500mg | 30,000 | tab | 6.50 | 195,000.00 | | | | | | | | | | |
| 26 | CAPD Solution 1.5% 2L with cap | 25,000 | bag | 206.00 | 5,150,000.00 | | | | | | | | | | |
| 27 | CAPD Solution 1.5% 5L with cap | 120 | bag | 568.00 | 68,160.00 | | | | | | | | | | |
| 28 | CAPD Solution 2.3% 2L with cap | 120 | bag | 206.00 | 24,720.00 | | | | | | | | | | |
| 29 | CAPD Solution 4.25% 2L with cap | 900 | bag | 206.00 | 185,400.00 | | | | | | | | | | |
| 30 | CAPD Solution 4.25% 5L with cap | 40 | bag | 568.00 | 22,720.00 | | | | | | | | | | |

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|-------|-----------------|--------------|------------------|--------|--------------|----------------------|---------------------|---|--------------------------------------|---|--|---|
| PROC | CURING ENTITY: PHILIPPINE | E CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REC | QUIRE | MENT | ٦ - | | | | | В | IDDER'S C | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 31 | Carbamazepine syr bt 100mg/5mL, 100mL | 300 | bt | 340.00 | 102,000.00 | | | | | | | | | | |
| 32 | Carbamazepine tab 200mg blister/foil pack | 30,000 | tab | 2.30 | 69,000.00 | | | | | | | | | | |
| 33 | Cefalexin Monohyd cap 500mg blister/foil pack | 500 | cap | 3.09 | 1,545.00 | | | | | | | | | | |
| 34 | Ceftazidime Pentahyd vl 1g (IM,IV) | 1,500 | vl | 148.00 | 222,000.00 | | | | | | | | | | |
| 35 | Ceftriaxone DiSod vl 1g + 10mL diluent (IV,IM) | 12,000 | vl | 120.00 | 1,440,000.00 | | | | | | | | | | |
| 36 | Cefuroxime Axetil tab 500mg blister/foil pack | 14,000 | tab | 12.00 | 168,000.00 | | | | | | | | | | |
| 37 | Cetirizine Dihydrochloride tab 10mg blister/foil pack | 20,000 | tab | 3.42 | 68,400.00 | | | | | | | | | | |
| 38 | Ciprofloxacin HCl tab 500mg blister/foil pack | 13,000 | tab | 8.15 | 105,950.00 | | | | | | | | | | |
| 39 | Clonazepam tab 2mg | 9,000 | tab | 8.50 | 76,500.00 | | | | | | | | | | |
| 40 | Clotrimazole 1% cream 10g | 80 | tbe | 60.00 | 4,800.00 | | | | | | | | | | |

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|-------------|-----------------|------------|------------------|--------|--------------|----------------------|--------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDR | EN'S ME | EDICAL C | ENTER | | | | | | NAME OF BI | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>1</u> | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REQ | QUIRE | MENT | . | | | | | В | IDDER'S C | OFFER | • | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 41 | Cotrimoxazole susp bt 200mg + 40mg/5mL, 60mL / 70mL | 5,000 | bt | 28.00 | 140,000.00 | | | | | | | | | | |
| 42 | Cotrimoxazole susp bt 400mg + 80mg/5mL, 60mL | 2,880 | bt | 37.00 | 106,560.00 | | | | | | | | | | |
| 43 | Cotrimoxazole tab/cap 800mg + 160mg blister/foil pack | 26,000 | cap/t ab | 2.00 | 52,000.00 | | | | | | | | | | |
| 44 | Cytarabine vl 1g, 10mL (IV inf) | 600 | vl | 935.00 | 561,000.00 | | | | | | | | | | |
| 45 | Cytarabine vl 500mg, 5mL (IV, SC infusion) | 500 | vl | 250.00 | 125,000.00 | | | | | | | | | | |
| 46 | Dactinomycin powd vl 500mcg | 350 | vl | 400.00 | 140,000.00 | | | | | | | | | | |
| 47 | Diazepam amp 5mg/mL, 2mL (IM,IV) | 600 | amp | 86.28 | 51,768.00 | | | | | | | | | | |
| 48 | Diazepam tab 5mg blister/foil pack | 200 | tab | 10.22 | 2,044.00 | | | | | | | | | | |
| 49 | Digoxin elix bt 50mcg/mL, 60mL | 80 | bt | 684.39 | 54,751.20 | | | | | | | | | | |
| 50 | Digoxin tab 250mcg | 2,500 | tab | 4.44 | 11,100.00 | | | | | | | | | | |

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|--|-------|--------------|-----------------|--------------|------------------|--------|--------------|----------------------|---------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDR | EN'S ME | DICAL C | <u>ENTER</u> | | | | | | NAME OF BI | DDER: | | |
| NAM | E OF PROJECT : PHARMACEUTI | CAL S | <u>UPPLI</u> | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REQ | QUIRE | MENT | 1 | | | | | В | IDDER'S C | OFFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 51 | Diphenhydramine HCl AF syr bt 12.5mg/5mL, 60mL | 400 | bt | 17.90 | 7,160.00 | | | | | | | | | | |
| 52 | Diphenhydramine HCl cap 25mg | 1,000 | cap | 1.10 | 1,100.00 | | | | | | | | | | |
| 53 | Diphenhydramine HCl cap 50mg blister/foil pack | 1,000 | cap | 1.10 | 1,100.00 | | | | | | | | | | |
| 54 | Domperidone susp bt 1mg/mL, 60mL | 400 | bt | 98.50 | 39,400.00 | | | | | | | | | | |
| 55 | Enoxaparin Sod prefilled syringe 100mg/mL, 0.4mL (SC) | 200 | pfs | 239.00 | 47,800.00 | | | | | | | | | | |
| 56 | Ephedrine Sulf amp 50mg/mL, 1mL (IV,SC) | 100 | amp | 84.00 | 8,400.00 | | | | | | | | | | |
| 57 | Epoetin A (RH Erythropoeitin) pfs 2000 IU/0.5mL (IV,SC) | 720 | pc | 320.00 | 230,400.00 | | | | | | | | | | |
| 58 | Erythromycin Stearate tab 500mg blister/foil pack | 300 | tab | 6.50 | 1,950.00 | | | | | | | | | | |
| 59 | Factor VIII Conc lyoph powd vl + diluent (IV) 52 IU/mL | 2,100 | vl | 3,600.00 | 7,560,000.00 | | | | | | | | | | |
| 60 | Ferrous Salt soln bt drp 15mg/0.6mL 15mL | 200 | bt | 21.00 | 4,200.00 | | | | | | | | | | |

| | | | | | | PI | RICE SO | CHEDU | LE | | | | | | |
|-------------|--|----------|-----------|----------------------|----------------|-----------------------|------------|-------------------|---------------------------|-------------------------|---|--------------------------|---|--|---|
| PROC | EURING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF BI | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REQ | | | | - | | | | B | IDDER'S C | | | | - | |
| ITEM NO. | 1 ITEM DESCRIPTION | 2 QTY | 3 UNIT | 4 ABC PER UNIT | 5 TOTAL ABC | 6 ITEM DESCRIPTION | 7 BRAND | 8 MANUFACTURER | 9 COUNTRY OF ORIGIN | 10 UNIT PRICE EXW | 11 COST OF LOCAL LABOR, RAW MATERIAL, | 12 TOTAL PRICE EXW | 13 UNIT PRICES FINAL DESTINATION AND UNIT PRICE | 14 SALES AND OTHER TAXES PAYABLE PER ITEM IF | 15 TOTAL PRICE DELIVERED FINAL |
| | | | | | | | | | | | AND COMPONENT | (cols. 2 x 10) | OF OTHER INCIDENTAL SERVICES | CONTRACT IS AWARDED | DESTINATION (col 13+14) x 2 |
| 61 | Ferrous Salt syr bt 30mg/5mL 60mL | 288 | bt | 14.48 | 4,170.24 | | | | | | | | | | |
| 62 | Ferrous Salt tab equiv 65mg EI | 10,000 | tab | 2.00 | 20,000.00 | | | | | | | | | | |
| 63 | Fluconazole vl 2mg/ mL, 100mL (IV inf) | 1,800 | vl | 500.00 | 900,000.00 | | | | | | | | | | |
| 64 | Fluticasone Propionate+Salmeterol Xinafoate 50/25mcg x 120 doses | 20 | pc | 157.85 | 3,157.00 | | | | | | | | | | |
| 65 | Glycerol Infant supp 1.9g | 480 | supp | 4.40 | 2,112.00 | | | | | | | | | | |
| 66 | Heparin Sod (unfractionated) vl 1000IU/mL, 5mL (IV,SC) | 6,000 | vl | 52.78 | 316,680.00 | | | | | | | | | | |
| 67 | Hydrocortisone Valerate 1% cream 10g | 150 | tbe | 115.00 | 17,250.00 | | | | | | | | | | |
| 68 | Hyoscine N-Butylbrom amp 20mg/ml, 1mL (IM,IV,SC) | 300 | amp | 21.64 | 6,492.00 | | | | | | | | | | |
| 69 | Ibuprofen susp bt 200mg/5mL, 60mL | 200 | bt | 65.15 | 13,030.00 | | | | | | | | | | |
| 70 | Immunoglobulin, Hepatitis B H vl 100IU 0.5mL | 60 | vl | 1,745.25 | 104,715.00 | | | | | | | | | | |

| | | | | | | PI | RICE S | CHEDU | LE | | | | | | |
|-------------|---|-------|-------|-----------------|------------|------------------|--------|--------------|----------------------|--------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAMI | E OF PROJECT : PHARMACEUTI | CAL S | UPPLI | ES CY 2021 | L | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REG | QUIRE | MENT | ٦ | | | | | В | IDDER'S C | OFFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 71 | Immunoglobulin, NH IGIV vl 500mg, 10mL | 30 | vl | 1,650.00 | 49,500.00 | | | | | | | | | | |
| 72 | Immunoglobulin, Rabies H vl 150IU/mL 2mL (IM) | 30 | vl | 3,000.00 | 90,000.00 | | | | | | | | | | |
| 73 | Immunoglobulin, Tetanus vl 250U/mL 1mL (IM) | 20 | vl | 700.00 | 14,000.00 | | | | | | | | | | |
| 74 | Influenza Polyvalent Vaccine 0.5mL prefilled syringe | 100 | pfs | 540.00 | 54,000.00 | | | | | | | | | | |
| 75 | Lagundi syr bt 300mg/5mL, 60mL | 120 | bt | 46.00 | 5,520.00 | | | | | | | | | | |
| 76 | Lansoprazole cap 15mg FDT blister/foil pack | 2,800 | cap | 52.00 | 145,600.00 | | | | | | | | | | |
| 77 | Lansoprazole cap 30mg FDT blister/foil pack | 700 | cap | 79.50 | 55,650.00 | | | | | | | | | | |
| 78 | Levobupivacaine HCl 5mg/mL soln for inj | 300 | vl | 231.00 | 69,300.00 | | | | | | | | | | |
| 79 | Levofloxacin 5mg/mL 0.5% ophthalmic solution | 30 | bt | 440.00 | 13,200.00 | | | | | | | | | | |
| 80 | Levothyroxin tab 100 mcg | 1,500 | tab | 7.02 | 10,530.00 | | | | | | | | | | |

Page 8 of 14

| | | | | | | PI | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|-------|-----------------|--------------|------------------|--------|--------------|----------------------|--------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAMI | E OF PROJECT : PHARMACEUTI | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REQ | UIRE | MENT | . | | | | | В | IDDER'S O | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 81 | Levothyroxin tab 50 mcg | 3,000 | tab | 3.58 | 10,740.00 | | | | | | | | | | |
| 82 | Lidocaine HCl + Epinephrine HCl carpule 2% 1.8mL | 200 | amp | 35.00 | 7,000.00 | | | | | | | | | | |
| 83 | Linezolid 600 mg tablet | 50 | tab | 1,800.00 | 90,000.00 | | | | | | | | | | |
| 84 | Loperamide HCl cap 2mg blister/foil pack | 1,000 | cap | 1.00 | 1,000.00 | | | | | | | | | | |
| 85 | Loratadine tab 10mg blister/foil pack | 3,000 | tab | 1.60 | 4,800.00 | | | | | | | | | | |
| 86 | Malunggay cap 300mg(Moringa Oleifera) blister/foil pack | 3,000 | cap | 3.30 | 9,900.00 | | | | | | | | | | |
| 87 | Mercaptopurine tab 50mg blister/foil pack | 90,000 | tab | 25.00 | 2,250,000.00 | | | | | | | | | | |
| 88 | Meropenem Trihydrate vl 1g (IV) | 10,000 | vl | 322.00 | 3,220,000.00 | | | | | | | | | | |
| 89 | Methimazole 5mg tab | 1,000 | tab | 5.07 | 5,070.00 | | | | | | | | | | |
| 90 | Methotrexate Sod (Preservative Free) vl 25mg/mL, 2mL (IM,IV,Intrathec) | 2,500 | vl | 205.50 | 513,750.00 | | | | | | | | | | |

| | | | | | | PI | RICE S | CHEDU | LE | | | | | | |
|-------------|---|--------|-------|-----------------|--------------|------------------|--------|--------------|----------------------|--------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF BI | DDER: | | |
| NAMI | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>-</u> | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REQ | QUIRE | MENT | 1 | | | | | В | IDDER'S C | FFER | 1 | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 91 | Methotrexate Sod tab 2.5mg blister/foil pack | 60,000 | tab | 8.79 | 527,400.00 | | | | | | | | | | |
| 92 | Metoclopramide HCl amp 5mg/mL, 2mL (IM,IV) | 400 | amp | 14.89 | 5,956.00 | | | | | | | | | | |
| 93 | Metronidazole vl 5mg/mL, 100mL (IV inf), sealed rubber cap | 3,500 | vl | 40.00 | 140,000.00 | | | | | | | | | | |
| 94 | Midazolam amp 15mg/3mL (IM,IV) | 12,000 | amp | 215.84 | 2,590,080.00 | | | | | | | | | | |
| 95 | Midazolam amp 5mg/mL, 1mL (IM,IV) | 500 | amp | 101.56 | 50,780.00 | | | | | | | | | | |
| 96 | Midazolam tab 15mg blister/foil pack | 200 | tab | 27.15 | 5,430.00 | | | | | | | | | | |
| 97 | Mineral Oil 1L | 25 | bt | 225.00 | 5,625.00 | | | | | | | | | | |
| 98 | Multivitamins drp bt 15mL | 500 | bt | 28.00 | 14,000.00 | | | | | | | | | | |
| 99 | Nalbuphine HCl amp 10mg/mL, 1 mL preservative free (IM, IV, SC) | 1,000 | amp | 90.00 | 90,000.00 | | | | | | | | | | |
| 100 | Naloxone HCl amp 400mcg/mL, 1mL (IM, IV, SC) | 20 | amp | 272.50 | 5,450.00 | | | | | | | | | | |

| | | | | | | P I | RICE S | CHEDU | LE | | | | | | |
|-------------|--|--------|-------|-----------------|------------|------------------|--------|--------------|----------------------|---------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| NAM | e of project : <u>PHARMACEUTI</u> | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. I | B-2021-025-A | | | | |
| | PCMC REC | QUIRE | MENT | 7 | | | | | В | IDDER'S O | FFER | • | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 101 | Olanzapine tab 10mg blister/foil pack | 9,000 | tab | 7.00 | 63,000.00 | | | | | | | | | | |
| 102 | Oxacillin Sod vl 500mg (IM, IV) | 4,000 | vl | 100.00 | 400,000.00 | | | | | | | | | | |
| 103 | Oxcarbazepine 300mg tablet | 18,000 | tab | 14.93 | 268,740.00 | | | | | | | | | | |
| 104 | Oxcarbazepine 60mg/mL, 100mL suspension | 1,000 | bt | 523.00 | 523,000.00 | | | | | | | | | | |
| 105 | Paracetamol tab 500mg blister/foil pack | 20,000 | tab | 0.40 | 8,000.00 | | | | | | | | | | |
| 106 | PD Extension Catheter | 40 | pc | 1,200.00 | 48,000.00 | | | | | | | | | | |
| 107 | PD Organizer | 40 | pc | 836.83 | 33,473.20 | | | | | | | | | | |
| 108 | Petroleum jelly 25g | 50 | jar | 33.41 | 1,670.50 | | | | | | | | | | |
| 109 | Phenobarbital Sod tab 30mg (gr1/2) | 20,000 | tab | 4.18 | 83,600.00 | | | | | | | | | | |
| 110 | Phenoxymethylpenicillin Pot cap 500mg blister/foil pack | 1,500 | cap | 17.48 | 26,220.00 | | | | | | | | | | |

| | PRICE SCHEDULE | | | | | | | | | | | | | | |
|-------------|---|--------|------|-----------------|--------------|------------------|-------------------------------------|--------------|----------------------|-------------------|--------------------------------------|--------------------------------------|---|--|--|
| PROC | URING ENTITY: PHILIPPINE | CHI | LDR | EN'S ME | DICAL C | ENTER | | | | | | NAME OF BIDDER: | | | |
| NAM | NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2021 | | | | | | INVITATION TO BID NO. IB-2021-025-A | | | | | | | | |
| | PCMC REQ | | | | | | | | B | IDDER'S O | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 COST OF LOCAL LABOR, | 12 | 13 UNIT PRICES FINAL | 14 SALES AND OTHER TAXES | 15 TOTAL PRICE DELIVERED |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | PAYABLE PER ITEM IF CONTRACT IS AWARDED | DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 111 | Piperacillin-Tazobactam Sod vl 4.5g (IM, IV) | 12,000 | vl | 185.00 | 2,220,000.00 | | | | | | | | | | |
| 112 | Prednisone tab 20mg blister/foil pack | 20,000 | tab | 4.20 | 84,000.00 | | | | | | | | | | |
| 113 | Ranitidine HCl amp 25mg/mL, 2mL (IM,IV,IV inf) | 800 | amp | 8.49 | 6,792.00 | | | | | | | | | | |
| 114 | Ranitidine HCl tab 150mg blister/foil pack | 800 | tab | 4.25 | 3,400.00 | | | | | | | | | | |
| 115 | Risperidone tab 1mg blister/foil pack | 14,000 | tab | 7.67 | 107,380.00 | | | | | | | | | | |
| 116 | Rituximab 100mg inj. 10mL vial | 10 | vl | 10,957.79 | 109,577.90 | | | | | | | | | | |
| 117 | Rituximab 500mg inj. 50mL vial | 30 | vl | 53,394.20 | 1,601,826.00 | | | | | | | | | | |
| 118 | Rocuronium Bromide vl 10mg/mL, 5mL (IV) | 1,700 | vl | 192.60 | 327,420.00 | | | | | | | | | | |
| 119 | Salbutamol Inhaler 100mcg x 200 dose | 1,000 | pc | 118.54 | 118,540.00 | | | | | | | | | | |
| 120 | Sertraline HCl tab 50mg blister/foil pack | 500 | tab | 7.92 | 3,960.00 | | | | | | | | | | |

| | PRICE SCHEDULE | | | | | | | | | | | | | | |
|-------------|--|-------|--------|-----------------|------------|------------------|-------|--------------|---------------------------------------|-------------------|---|--------------------------------------|---|--|---|
| PROC | CURING ENTITY: PHILIPPINE | CHI | LDRI | EN'S ME | DICAL C | ENTER | | | | | | NAME OF BIDDER: | | | |
| NAM | NAME OF PROJECT : PHARMACEUTICAL SUPPLIES CY 2021 | | | | | | | | INVITATION TO BID NO. $IB-2021-025-A$ | | | | | | |
| | PCMC REG | QUIRE | MENT | 7 | | | | | В | IDDER'S O | FFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 121 | Sevelamer Carbonate 800mg powder for suspension | 800 | sachet | 87.00 | 69,600.00 | | | | | | | | | | |
| 122 | Sevelamer Carbonate 800mg tablet | 3,990 | tab | 38.79 | 154,772.10 | | | | | | | | | | |
| 123 | Sodium Bicarbonate vl 1mEq/mL, 50mL (IV inf) | 5,000 | vl | 100.00 | 500,000.00 | | | | | | | | | | |
| 124 | Sodium Valproate 200 mg/5mL Syr 100mL | 500 | bt | 187.00 | 93,500.00 | | | | | | | | | | |
| 125 | Streptomycin Sulf vl 1g (IM) | 50 | vl | 23.32 | 1,166.00 | | | | | | | | | | |
| 126 | Terbutaline Sulf amp 500mcg/mL, 1mL (IV) | 100 | amp | 65.00 | 6,500.00 | | | | | | | | | | |
| 127 | Tobramycin Eye Drp bt 0.3% 5mL | 40 | tbe | 165.00 | 6,600.00 | | | | | | | | | | |
| 128 | Tramadol HCl amp 50mg/mL, 1mL (IM,IV,SC) | 2,000 | amp | 25.00 | 50,000.00 | | | | | | | | | | |
| 129 | Tramadol HCl cap 50mg blister/foil pack | 5,000 | cap | 1.95 | 9,750.00 | | | | | | | | | | |
| 130 | Tranexamic Acid cap 500mg blister/foil pack | 5,000 | cap | 6.15 | 30,750.00 | | | | | | | | | | |

| | PRICE SCHEDULE | | | | | | | | | | | | | | |
|-------------|--|-------------|--------------|-------------------|----------------------|----------------------------------|-----------------------------|-------------------------|----------------------|--------------------|---|--------------------------------------|---|--|---|
| PROC | ROCURING ENTITY: PHILIPPINE CHILDREN'S MEDICAL CENTER | | | | | | | | | NAME OF B | IDDER: | | | | |
| NAMI | E OF PROJECT : PHARMACEUTI | CAL S | UPPLI | ES CY 2021 | <u>L</u> | | | | INVITATION | to bid no. ${f I}$ | B-2021-025-A | | | | |
| | PCMC REQ | QUIRE | MENT | 1 | | | | | В | SIDDER'S C | OFFER | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13+14) x 2 |
| 131 | Tropicamide + Phenylephrine HCl 5mg + 5mg/mL eye drops 10mL | 100 | bt | 665.00 | 66,500.00 | | | | | | | | | | |
| 132 | Tuberculin PPD powd 5TU w/ 2mL diluent | 40 | vl | 1,171.50 | 46,860.00 | | | | | | | | | | |
| 133 | Vaccine, Rabies Vero Cell vl 2.5 IU/monodose + dil (IM) | 100 | vl | 1,281.50 | 128,150.00 | | | | | | | | | | |
| 134 | Valproic Acid 500mg/5mL (IV infusion) | 400 | vl | 1,871.35 | 748,540.00 | | | | | | | | | | |
| 135 | Water for Injection glass bt 500mL | 3,000 | bt | 103.00 | 309,000.00 | | | | | | | | | | |
| ADD | ITIONAL REQUIREMENTS: | | | | • | | | | тот | AL = | | | | | |
| ≻ Cont | orme on the attached Terms of Reference, i | f applicab | ole | | | | | | | | TERMS OF RANAGE | | - h-in 66 d - 6-43 | ende ener Other i | |
| ≻ Drug | s and Medicines to be delivered should have | e expiratio | on of at lea | st one (1) year a | and longer or as exp | pressed/ required by Pharmacy | | | | | TERMS OF PAYME | IN 1 (For discount | s being offered, if th | ere s any. Otherwise, | , state "NONE") : |
| | > The price of the bided item(s) shall be valid until December 31, 2021 | | | | | | | | | | | | | | |
| | gered delivery, staggered payment | | | | | | | | | | | | | | |
| | quantities specified are estimated requirements es called for on this biddin | nts during | the period | 1 and may be dee | creased depending | upon the actual need of PCMC. It | is understood therefore the | tt PCMC is not bound to | order / purchase a | all the items / | | | | | |
| ≻ The | supplier should submit Materials Safety Data | a Sheet up | pon deliver | y, if applicable | | | | | | | NAI | ME AND SIGNAT | TURE OF AUTHORIZ | LED REPRESENTAT | TIVE |
| | PCMC has the right to reject any or all bids without offering any reason, waive any required formality and award the contract to any bidder who overnment. | | | | | r whose proposals as eval | nated by PCMC is the mo | ost advantageous t | to the | BAC & END-USER'S | S SIGNATURE: | | | | |

| | | | | | | P | RICE S | CHEDU | JLE | | | | | | |
|-----------------|--|---------------|------------|-------------------|----------------------|-------------------------------------|----------------------------|--------------------------|----------------------|------------------------------------|---|--------------------------------------|---|--|---|
| PROC | URING ENTITY: PHILIPPIN | E CHI | LDR | EN'S ME | EDICAL C | ENTER | | | | | | NAME OF B | DDER: | | |
| | E OF PROJECT : PHARMACEUT | | | | | | | | INVITATION | N TO BID NO.] (VAT EXEN | [B-2020-025-B (IPT) | | | | |
| | PCMC RE | QUIRE | MENT | Γ | | | | | E | BIDDER'S C | OFFER | • | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| ITEM NO. | ITEM DESCRIPTION | QTY | UNIT | ABC PER UNIT | TOTAL ABC | ITEM DESCRIPTION | BRAND | MANUFACTURER | COUNTRY OF ORIGIN | UNIT PRICE EXW | COST OF LOCAL LABOR, RAW MATERIAL, AND COMPONENT | TOTAL PRICE EXW (cols. 2 x 10) | UNIT PRICES FINAL DESTINATION AND UNIT PRICE OF OTHER INCIDENTAL SERVICES | SALES AND OTHER TAXES PAYABLE PER ITEM IF CONTRACT IS AWARDED | TOTAL PRICE DELIVERED FINAL DESTINATION (col 13 + 14) x 2 |
| 1 | Amlodipine Besylate tab 10mg blister/foil pack | 25,000 | tab | 1.00 | 25,000.00 | | | | | | | | | | |
| 2 | Amlodipine Besylate tab 5mg blister/foil pack | 55,000 | tab | 0.92 | 50,600.00 | | | | | | | | | | |
| 3 | Enalapril Maleate tab 5mg blister/foil pack | 21,000 | tab | 4.00 | 84,000.00 | | | | | | | | | | |
| 4 | Irbesartan 300 mg | 500 | tab | 8.31 | 4,155.00 | | | | | | | | | | |
| 5 | Losartan tab 50mg | 70,000 | tab | 2.00 | 140,000.00 | | | | | | | | | | |
| 6 | Methyldopa tab 250mg blister/foil pack | 1,000 | tab | 9.28 | 9,280.00 | | | | | | | | | | |
| 7 | Spironolactone tab 25mg blister/foil pack | 2,000 | tab | 15.00 | 30,000.00 | 343,035.00 | | | | | | | | | |
| ADD | ITIONAL REQUIREMENTS: | | | | | | | | ТОТ | AL = | | | | | |
| ≻ Con | forme on the attached Terms of Reference | , if applicab | le | | | | | | | | TERMS OF PAYME | NT (For discount | s heing offered if th | ere's any Otherwise | state "NONF") · |
| | gs and Medicines to be delivered should ha | - | | - | and longer or as ex | pressed/ required by Pharmacy | | | | | LINID OF TATME | and a croir unscould | o ocing oncicu, ii tii | ere 5 any. Other wise | , state 1101112) . |
| | price of the bided item(s) shall be valid unt | til Decembe | er 31, 202 | 1 | | | | | | | 4 | | | | |
| | gered delivery, staggered payment | | | | | | | | | | | | | | |
| | quantities specified are estimated requirem ies called for on this biddin | ents during | the perio | d and may be de | ecreased depending | g upon the actual need of PCMC. It | is understood therefore th | at PCMC is not bound to | order / purchase | all the items / | | | | | |
| ≻ The | supplier should submit Materials Safety Da | ata Sheet up | on delive | ry, if applicable | | | | | | | | | URE OF AUTHORI | ZED REPRESENTA | TIVE |
| ≻ PCM govern | AC has the right to reject any or all bids wit ment. | thout offerir | ng any rea | ason, waive any i | required formality a | and award the contract to any bidde | er whose proposals as eval | luated by PCMC is the me | ost advantageous | to the | BAC & END-USER'S | S SIGNATURE: | | | |



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: www.pcmc.gov.ph email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION I

Invitation to Bid

Supply and Delivery of Various Pharmaceutical Supplies CY 2021



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER

Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: <u>officeofthedirector@pcmc.gov.ph</u> Trunkline: 588-9900 DirectLine: 924-0836 Fax No: 924-0840

INVITATION TO BID

SUPPLY AND DELIVERY OF VARIOUS PHARMACEUTICAL FOR CY 2021 VARIOUS COMMON NON-MEDICAL SUPPLIES CY 2021

1. The Philippine Children's Medical Center (PCMC) through the GAA CY 2021 intends to apply the sum of Forty-Six Million Five Hundred Thirteen Thousand Six Hundred Thirty-Eight Pesos & 51/100) (Php 46,513,638.51) being the Approved Budget for the Contract (ABC) to payments under the following Invitation to Bid. Bids received in excess of the ABC shall be automatically rejected at bid opening.

| IB NO. | ITEM DESCRIPTION | ABC (Php) | Cost of Complete Set of Bidding documents |
|-------------|---|---------------|---|
| IB 2021-025 | Various Pharmaceutical Supplies CY 2021 | 45,162,409.06 | 25,000.00 |
| IB 2021-026 | Various Common Non-Medical Supplies CY 2021 | 1,351,229.45 | 5,000.00 |

2. The Philippine Children's Medical Center (PCMC) now invites bids for the above-mentioned project. Delivery of the Goods is required within Seven (7) calendar days. Bidders should have completed, within the past two (2) years from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II. Instructions to Bidders.

3. Bidding will be conducted through open competitive bidding procedures using a nondiscretionary "pass/fail" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, otherwise known as the "Government Procurement Reform Act".

a. Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

4. Prospective Bidders may obtain further information from PCMC and inspect the Bidding Documents at the address given below during office hours.

5. A complete set of Bidding Documents may be acquired by interested Bidders starting November 26, 2020 upon payment of the applicable fee stated above. It may also be downloaded free of charge from the website of the Philippine Government Electronic Procurement System (PhilGEPS) and the website of PCMC, provided that Bidders shall pay the applicable fee for the Bidding Documents not later than the submission of their bids.

PhilHealth Accredited



6. The Philippine Children's Medical Center will hold a **Pre-Bid Conference** on **December 4, 2020** at **10:00 A.M.** through video conferencing via *google meet* which shall be open to prospective bidders.

7. Bids must be duly received by the BAC Secretariat through manual submission on or before **December 16, 2020 9:30 A.M., Guard-on-Duty, 3rd Floor, Procurement Division Area, PCMC Main Building.** Late bids shall not be accepted.

8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 14.

9. Bid opening shall be on **December 16, 2020 10:00 A.M. 3rd Floor, Function Hall, PCMC Main Building**. Bids will be opened in the presence of the Bidders' representatives who choose to attend at the afore-mentioned venue. In compliance to social distancing and to support the government's effort to mitigate, if not contain the transmission of COVID-19, we will strictly allow only one authorized representative per bidder company to enter the venue during opening of bids. Provided further, that said authorized representative shall wear PPE and shall pass the triage areas as required prior entering PCMC Premises.

10. The **Philippine Children's Medical Center (PCMC)** reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.

11. For further information, please refer to:

PCMC BAC Secretariat 3rd Floor, Procurement Division PCMC Main Building Quezon Avenue, cor. Agham Road Quezon City Trunkline : 8588-9900 Loc 361 / 355 Fax Number: 924-0870 Email : pcmcbac@gmail.com

12. You may visit the following websites:

For downloading of Bidding Document : <u>www.pcmc.gov.ph</u> www.philgeps.gov.ph

November 25, 2020

MARIA ROSARIO S. CRUZ, MD Chairman, Bids & Awards Committee v

IB-2021-025 to 2021-026

Page 2 of 2



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: <u>bac@pcmc.gov.ph</u> Trunkline: 588-9900 local 361/355 Telefax No.: 924-0870

SECTION II

Instructions to Bidders

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

1. Scope of Bid

The Philippine Children's Medical Center (PCMC) wishes to receive Bids for the following Project:

| IB NUMBER | ITEM DESCRIPTION | TOTAL ABC |
|-------------|---|---------------|
| IB-2021-025 | Supply and Delivery of Various Pharmaceutical Supplies CY 2021 (rebid) | 45,162,409.06 |

The above Procurement Projects, the details of which are described in Section VII (Technical Specifications).

2. Funding Information

- 2.1. The GOP through the source of funding as indicated below for CY 2021 in the amount of Forty-Five Million One Hundred Sixty-Two Thousand Four Hundred Nine Pesos and 06/100 (Php 45,162,409.06).
- 2.2. The source of funding is:
 - a. GOCC and GFIs, the Corporate Operating Budget (*Revolving Fund*)

3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **IB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

5. Eligible Bidders

5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

- a. Foreign ownership exceeding those allowed under the rules may participate pursuant to:
 - i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;
 - ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;
 - iii. When the Goods sought to be procured are not available from local suppliers; or
 - iv. When there is a need to prevent situations that defeat competition or restrain trade.
- 5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:
 - a. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC of the items joined.
 - b. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: [Select either failure or monopoly of bidding based on market research conducted]
 - i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies*] of the ABC for this Project; and
 - ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.
- 5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

a. Subcontracting is not allowed.

8. Pre-Bid Conference

The Philippine Children's Medical Center will hold a Pre-Bid Conference on **December** 4, 2020 at 10:00 A.M. through video conferencing via google meet which shall be open to prospective bidders, as indicated in paragraph 6 of the IB.

9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10. Documents comprising the Bid: Eligibility and Technical Components

- 10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in Section VIII (Checklist of Technical and Financial Documents).
- 10.2. The Bidder's SLCC as indicated in **ITB** Clause 5.3 should have been completed within **the past two (2) years** prior to the deadline for the submission and receipt of bids.
- 10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

11. Documents comprising the Bid: Financial Component

- 11.1. The second bid envelope shall contain the financial documents for the Bid as specified in Section VIII (Checklist of Technical and Financial Documents).
- 11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.
- 11.3. Any bid exceeding the ABC indicated in paragraph 1 of the IB shall not be accepted.

11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

12. Bid Prices

- 12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:
 - a. For Goods offered from within the Procuring Entity's country:
 - i. The price of the Goods quoted EXW (ex-works, ex-factory, exwarehouse, ex-showroom, or off-the-shelf, as applicable);
 - ii. The cost of all customs duties and sales and other taxes already paid or payable;
 - iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and
 - iv. The price of other (incidental) services, if any, listed in e.
 - b. For Goods offered from abroad:
 - i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.
 - ii. The price of other (incidental) services, if any, as listed in Section VII (Technical Specifications).

13. Bid and Payment Currencies

- 13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.
- 13.2. Payment of the contract price shall be made in:
 - a. Philippine Pesos.

14. Bid Security

14.1. The Bidder shall submit a Bid Securing Declaration¹ or any form of Bid Security in the amount indicated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.

14.2. The Bid and bid security shall be valid until *120 calendar days*. Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

15. Sealing and Marking of Bids

Use of indelible ink <u>color blue</u> shall be used by the authorized signatory in signing the required forms. *Strictly NO using of staple wire and thick materials for tab*

The **First** (1st) **Envelope**, shall contain the following <u>Technical Documents</u> accomplished in two (2) sets, **each set filed in a folder**

The Second (2^{nd}) Envelope shall contain the Financial Component accomplished in three (3) sets, each set filed in a folder

All copies should be certified as true copy

| COLOR CODING OF | DINL |
|-------------------|------|
| FOLDERS/ENVELOPES | LINK |

LABEL ON THE ENVELOPE/S: Name of PROCURING ENTITY

Name of FROCOKING ENTITY Name of CONTRACT TO BE BID IB Number DATE of Bid Opening Name of the Bidder Company Address of the Bidder Company

IDENTIFY THE ENVELOPES:

- as: > Technical Component Requirements (original and copy 1)
 - > Financial Component Requirement (original, copy 1, copy 2)

16. Deadline for Submission of Bids

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB**.

17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

19. Detailed Evaluation and Comparison of Bids

19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated "*passed*," using non-discretionary pass/fail criteria. The BAC shall consider

the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.

- 19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.
- 19.3. The descriptions of the lots or items shall be indicated in Section VII (Technical Specifications), although the ABCs of these lots or items are indicated in the BDS for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.
- 19.4. The Project shall be awarded as follows:

Option 3 - One Project having several items, which shall be awarded as separate contracts per item.

19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

20. Post-Qualification

20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**.

21. Signing of the Contract

21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

CONFORME:

Authorized Signatory Signature over printed name

Name of Company/Firm



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION III

Bid Data Sheet

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

| ITB Clause | | | | | | | | | |
|---------------|---|--|---|--|--|--|--|--|--|
| 5.3 | For this purpose, con | tracts similar to the Project shall be: | | | | | | | |
| | a. Supply and de | elivery of <i>Pharmaceutical Supplies</i> . | | | | | | | |
| | b. completed wi receipt of bids | | | | | | | | |
| 7.1 | Subcontracting is not al | | | | | | | | |
| 12 | The Bid prices for Goo Pesos. | The Bid prices for Goods supplied from outside of the Philippines shall be quoted in Philippine Pesos. | | | | | | | |
| 14.1 | The bid security shall forms and amounts: | The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts: | | | | | | | |
| | 1. The amount of not less than <u>two percent (2%) of the ABC of the item(s) joined</u> , if bid security is in cash, cashier's/manager's check, bank draft/guarantee or irrevocable letter of credit; or | | | | | | | | |
| | 2. The amount of a bid security is in | not less than <u>five percent (5%) of the ABC</u> Surety Bond. | <u>C of the item(s) joined</u> , if | | | | | | |
| 19.3 | Supply and Delivery of | f the following: | | | | | | | |
| | IB NUMBER | ITEM DESCRIPTION | TOTAL ABC | | | | | | |
| | IB-2021-025 | Pharmaceutical Supplies CY 2021 (rebid) | 45,162,409.06 | | | | | | |
| 20.2 | extendible period of <i>fiv</i> following: 1. Latest Income Filing (EFPS) 2. Valid and currer 3. Manufacturer's certification freproducts / item | Bidder shall submit the following documentary <i>be (5) calendar days</i> from receipt of the notification and Business Tax Returns filed and paid through within the last three (3) months ent Certificate of PhilGEPS Registration. Is Certification or if the Bidder is not a manufactor of the manufacturer as authorized or exclusive s. | ion that contain the a the BIR Electronic cturer, authenticated copy of e distributor or dealer of the | | | | | | |

Bid Data Sheet

1

| | 6. Consumer guidelines regarding disposal of the supplies (<i>Information about how and where the used/decommissioned products/ packaging/parts can be returned for recycling and/or disposal e.g. buy-back program</i>) 7. Other appropriate licenses and permits required by law and stated in the Bidding Documents |
|------|---|
| | Failure of the Bidder declared as LCB to duly submit the requirements stated above or a finding against the veracity of such shall be ground for forfeiture of the bid security and disqualify the Bidder for award. |
| | Note: Requirement Nos. 3 to 6 for items JOINED must be accomplished and submitted using the Summary Sheet to be provided by PCMC. |
| 21.2 | No additional contract documents relevant to the Project |

CONFORME:

Authorized Signatory Signature over printed name

Name of Company/Firm



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION IV

General Conditions of Contract

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract (SCC).**

2. Advance Payment and Terms of Payment

- 2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.
- 2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the SCC.

[Include the following clauses if Framework Agreement will be used:]

- 2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.
- 2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184.{[Include if Framework Agreement will be used:] In the case of Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.}

4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project *{[Include if Framework Agreement will be used:]* or Framework Agreement*}* specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the **SCC**, **Section IV (Technical Specifications)** shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity

shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

5. Warranty

- 6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.
- 6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

CONFORME:

Authorized Signatory Signature over printed name

Name of Company/Firm



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION V

Special Conditions of Contract

Supply and Delivery of

Various Pharmaceutical Supplies CY 2021

GCC Clause For Goods supplied from within the Philippines: Upon delivery of the Goods to the Project Site, the Supplier shall notify the Procuring Entity and present the following documents to the Procuring Entity: (i) Original and four copies of the Supplier's invoice showing Goods' description, quantity, unit price, and total amount; (ii) Four copies of Material Safety Data Sheet for a specified product upon initial delivery Packaging -The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit The packaging, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity. The Supplier shall have an established disposal and retrieval program or take back system for their products (items with container) 1 The Supplier shall submit MSDS for a specified product. 2. The product label shall bear the following information: a. Product specifications and ingredients b. Manufacturing and Expiration Dates c. Precautions d. Instructions for proper use and disposition e. Hazardous items shall be properly labeled as a hazardous product (e.g. flammable cytotoxic, radioactive, poison, etc.) 3. The product shall not contain halogenated plastics and PVCs. 4. The product shall be packed in suitable packaging materials which are reusable and recyclable. Transportation – Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price.

Special Conditions of Contract

| - | |
|-----|--|
| | Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the Procuring Entity certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure. |
| | The Procuring Entity accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination. |
| | Intellectual Property Rights – |
| | The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof. |
| 2.2 | The terms of payment shall be on Acceptance: |
| | 100% of the Contract Price per Delivery Order Slip shall be paid to the Supplier within 30 to 45 days or Supplier's credit term after final acceptance and submission of required documents. |
| 3 | Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security. |
| 4 | The inspections and tests that will be conducted are: 1) Upon delivery, the Goods shall undergo preliminary physical inspection by the Inspection Team of the PROCURING ENTITY to ascertain the physical condition and acceptability of the Goods. |
| | 2) The supplier shall promptly replace the equivalent quantity of Goods taken as samples without cost to the PROCURING ENTITY. |
| 5 | Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are consumed, whichever is earlier. |
| | Winning bidder has to choose the following mode (as checked) as the form of retention money required of under R.A 9184 Sec. 62.1 |
| | [] Bank Guarantee[] 5% Deduction from claims |
| | The said amount shall only be released after the lapse of the warranty period specified in Section VII Technical Specification; provided, however, that the Supplies delivered are free from patent and latent defects and all the conditions imposed under this Contract have been fully met. |

CONFORME:

Authorized Signatory Signature over printed name

Name of Company/Firm



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VI

Schedule of Requirements

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-025

The delivery schedule expressed as weeks/months stipulates hereafter a delivery date which is the date of delivery to the project site.

| Description | Total ABC (Php) | Delivery Site | PCMC Requirement DELIVERY PERIOD |
|--|--------------------|---|---|
| Various Pharmaceutical Supplies CY 2021 (rebid) | Php45,162,409.06 | Materials Management Division, G/F PCMC, Quezon Avenue, cor . Agham Road Quezon City | Within seven (7) working days from receipt of DELIVERY ORDER SLIP |

DELIVERY AND ACCEPTANCE

- Staggered delivery and staggered payment
- Supplies to be delivered should have an expiration at least one (1) year and longer or as expressed/required by the end-user.
- The Supplier should submit Materials Safety Data Sheet upon initial delivery, if applicable.
- The supplier should deliver the goods called for in the Purchase Order (PO) within seven (7) working days or as stated on Delivery Period upon receipt of approved Delivery Order Slip, faxed or personally received during office hours at the Procurement Section.
- All goods delivered pursuant to the Purchase Order (PO) with Delivery Order Slip shall be subject to acceptance and inspection by the end-user as well as by the House Inspector and of the Resident Auditor or their representatives. Goods delivered not in conformity with specifications shall be rejected and the contractor held in default.

CONFORME:

NAME OF COMPANY

ADDRESS

SIGNATURE OVER PRINTED NAME OF AUTHORIZED REPRESENTATIVE

TELEPHONE / FAX



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VII

Technical Specifications

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-025



Republic of the Philippines DEPARTMENT OF HEALTH PHILIPPINE CHILDREN'S MEDICAL CENTER Bids and Awards Committee Quezon Avenue, Quezon City 1100 website: <u>www.pcmc.gov.ph</u> email: pcmcbac@gmail.com Trunkline: 8588-9900 local 361/355 Telefax No.: 8924-0870

SECTION VIII

Checklist of Technical and Financial Documents

Supply and Delivery of Various Pharmaceutical Supplies CY 2021

IB-2021-025

Checklist of Technical and Financial Documents

The Bidder shall submit the following <u>TECHNICAL COMPONENT ENVELOPE</u> (<u>ARRANGED, NUMBERED AND TABBED</u>) [Strictly NO using of staple wire and thick materials for tabs] as enumerated below:

I. TECHNICAL COMPONENT ENVELOPE

Class "A" Documents

Legal Documents

1. Valid PhilGEPS Registration Certification (Platinum Membership) and its Annex A.

<u>or</u>

2. Registration certificate from Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or Cooperative Development Authority (CDA) for cooperatives or its equivalent document,

and

3. Mayor's/Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located or the equivalent document for Exclusive Economic Zones or Areas.

and

4. Valid Tax Clearance per Executive Order 398, series of 2005, as finally reviewed and approved by the BIR.

Note:

In the event the bidder opted to submit only Requirement Nos. 2 to 4 Legal Documents, the Certificate of PhilGEPS Registration (Platinum Membership) shall remain a postqualification requirement to be submitted in accordance with Section 34.2 of the 2016 Revised IRR of RA 9184 (Pursuant to GPPB Circular 07-2017 dated 31 July 2017)

Technical Documents

- 5. Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid. (Use of Form No. DOBA-PCMC-SCF3b is required)
- 6. Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid (Refer to Bid Data Sheet ITB Clause 5.3), except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within two (2) years prior to bid opening (use of Form No. DOBA-PCMC-SCF3a is required).
- 7. Bid Security (Refer to Bid Data Sheet ITB Clause 14.1)
- 8. Duly accomplished and signed Production/ Delivery Schedule using the form as provided for in Section VI

- 9. Duly accomplished and signed Technical Specification using the form as provided for in Section VII
- 10. Omnibus Sworn Statement (Use of the Form provided is required)
- 11. Certificate of Performance in letterhead of their clients indicating the contact numbers and email addresses signed by the authorized head of the Department from three (3) clients of the bidder issued within the last six (6) months prior to bid opening.
 - *Note:* Certification issued by PCMC Procurement Section must be included if bidder had done business with us. Certification of which should be of same category (e.g. equipment/supplies) of project being bided.
- 12. Valid and current License to Operate (LTO) issued by Food and Drug Administration (FDA).

Financial Documents

- 1. The prospective bidder's Audited Financial Statements, showing, among others, the prospective bidder's total current assets and liabilities, stamped "received" by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of submission.
- 2. The prospective bidder's computation of the Net Financial Contracting Capacity (NFCC) that must be at least equal to the ABC to be bid (*Use of Form No. DOBA–PCMC–NFF4 is required*);

OR,

a committed Line of Credit from a Universal or Commercial Bank, in lieu of its NFCC computation, it must be at least equal to 10% of the ABC.

Class "B" Documents

1. For Goods, valid joint venture agreement (JVA), in case the joint venture is already in existence. In the absence of a JVA, duly notarized statements from all the potential joint venture partners should be included in the bid, stating that they will enter into and abide by the provisions of the JVA in the event that the bid is successful. Failure to enter into a joint venture in the event of a contract award shall be ground for the forfeiture of the bid security. (Use of Form No. DOBA-PCMC-JVF6 is required).

Each partner of the joint venture shall submit their legal eligibility documents or Certificate of PhilGEPS Registration (Platinum Membership). The submission of technical and financial eligibility documents by any of the joint venture partners shall constitute compliance: Provided, That the partner responsible to submit the NFCC shall likewise submit the Statement of all its ongoing contracts and Audited Financial Statements. The Bidder shall submit the following <u>FINANCIAL COMPONENT ENVELOPE</u> (<u>ARRANGED</u>, <u>NUMBERED AND TABBED</u>) [Strictly NO using of staple wire and thick materials for tabs] as enumerated below:

II. FINANCIAL COMPONENT ENVELOPE

- 1. Duly accomplished and signed Bid Form
- 2. Duly accomplished and signed **Price Schedule** using the form as provided

Note: Bidder shall return to PCMC the issued USB Flash Drive containing the soft copy of their accomplished Price Schedule (in excel format).

- 3. Signed Conforme on the Terms of Reference, if applicable
- 4. Section II. Instructions to Bidders with signature (conforme) on all pages.
- 5. Section III. Bid Data Sheet with signature (conforme) on all pages.
- 6. Section IV. General Conditions of the Contract with signature (conforme) on all pages.
- 7. Section V. Special Conditions of the Contract with signature (conforme) on all pages.
- 8. Certification for Assurance of Stocks Availability [use of Form No. DOBA-PCMC-CAF10 is required]
- 9. Return Policy [use of Form No. DOBA PCMC CRF34 is required]

CONFORME:

Authorized Signatory Signature over printed name

Quezon Avenue, Quezon City

TERMS OF REFERENCE CY 2021

BLOOD SUGAR STRIPS

- 1. The winning bidder for Blood Sugar Strips shall have a one year contract in supplying the requirements of PCMC.
- 2. The supplier shall provide the complete set of Blood Sugar Monitor (BSM) that includes lancet (with holder/launcher, if applicable) and batteries for the glucometer within the contract period.
- 3. The supplier shall provide BSM Machine to all Pay, Service wards, and Specialty Wards.

Pay Wards: 2A and 2B

Service Wards: NBS, 1B Subspecialty, 1B Surgery, and CNS

Specialty Areas (Pay and Service): ER, ER triage, Ward-19, Hema-Onco, Peritoneal Dialysis Unit, Hemodialysis Unit, NICU, RICU, SICU, OR, Heart Institute, and Perinatal Center.

4. The supplier shall be responsible for the preventive maintenance at least twice a month within the contract period with no additional cost to PCMC. This shall include:

Calibration and repair of the BSM machine

Replacement for the Blood Sugar Strips used during calibration of BSM machine

Replacement of defective parts

Provision of a back-up unit should any BSM machine be found defective and has to be pulled out for repair within the contract period.

Provide replacement for used-up batteries of the BSM machine.

5. The supplier shall submit a service report to end user for record/documentation purposes, such as:

Repair Service Report

Preventive Maintenance Service

Certification of Calibration

6. The supplier shall accommodate emergency calls during office hours in the event that any of the BSM machine in the hospital is non-operational.

CONFORME :

Authorized Signatory Signature over printed name

Quezon Avenue, Quezon City

TERMS OF REFERENCE

CY 2021

HAZARDOUS PHARMACEUTICALS

- 1. The winning bidders for hazardous pharmaceuticals (see attached list) shall provide PCMC two copies (one for Property and Supply and one for the Pharmacy Division) of the corresponding Materials Safety Data Sheet (MSDS) of said medicine/galenicals upon delivery.
- 2. The supplier shall make sure that these pharmaceuticals are properly packed for safety from breakage and spills upon delivery to PCMC. Likewise, these pharmaceuticals shall be properly labeled as a hazardous product (e.g., flammable, cytotoxic, radioactive, poison.etc.).
- 3. Suppliers shall provide the PCMC with the appropriate Spill Kit upon the request of the Pharmacy Division for use in the wards/clinical areas using these products.
- 4. The supplier shall be responsible in disposing the expired and defective hazardous pharmaceuticals. The Pharmacy Division shall inform the corresponding supplier three months before the expiry date of their product. The supplier shall be informed about the defective products as soon as it has been detected.
- 5. Upon request of the corresponding end-user, the supplier shall provide training on safe handling of their product(s), including management of spills.

CONFORME :

Authorized Signatory Signature over printed name

LIST OF HAZARDOUS PHARMACEUTICALS

- 1. Bleomycin Sulfate 15 mg inj.
- 2. Calcium Folinate 50 mg inj.
- 3. Carboplatin 150 mg vl.
- 4. Cisplatin 50 mg vl
- 5. Cyclophosphamide 200 mg, 500 mg vl; 50 mg tablet
- 6. Cytarabine 100 mg, 500 mg, and 1 g vl.
- 7. Dactinomycin 500 mcg inj
- 8. Dacarbazin 200 mg vl.
- 9. Doxorubicin 10 mg, 20 mg, and 50 mg vl
- 10. Etoposide 20 mg/ml, 5 mL inj
- 11. Fluorouracil vl 500mg IV
- 12. Hydroxyurea 500 mg capsule
- 13. Idarubicin HCl 5 mg inj.
- 14. Ifosfamide 1 g and 2 g vl
- 15. Imatinib 100 mg tablet
- 16. Irinotecan 100 mg/5mL and 40 mg/2mL (HCl) concentrate, vl (IV infusion)
- 17. L-asparaginase 10,000 IU vl
- 18. Mercaptopurine 50 mg tab
- 19. Methotrexate 500 mg, 1 g, and 50 mg vl; 2.5 mg tablet
- 20. Mitoxanthrone 20 mg Inj.
- 21. Paclitaxel 6mg/mL 17mL (IV) vl
- 22. Rituximab 500mg inj. 50mL vial and 100mg inj. 10mL vial
- 23. Vinblastine 10 mg Inj
- 24. Vincristine 1 mg and 2 mg inj.
- 25. Povidone Iodine solution (all dosage preparations)
- 26. Gadoteric acid (all dosage preparations)
- 27. Iodixanol (all dosage preparations)
- 28. Iohexol (all dosage preparations)
- 29. Ioversol (all dosage preparations)
- 30. Iopamidol (all dosage preparations)
- 31. Sevoflurane Inhalation 250 mL
- 32. Isoflurane Inhalation 100 mL

CONFORME :

Authorized Signatory Signature over printed name

Quezon Avenue, Quezon City

TERMS OF REFERENCE CY 2021

Pharmaceutical Products, Containers, and Devices

The following are the requirements to winning suppliers in compliance with Administrative Order No. 2019-0041, dated October 4, 2019 re: *Implementing Guidelines in Assuring the Efficacy, Quality, and Safety of Pharmaceutical Products in the Public Health Facilities*;

1. All pharmaceutical products and devices shall be of fresh commercial stock as reflected in the Certificate of Product Registration (CPR) issued by the FDA upon delivery. The acceptable shelf life upon delivery is as follows:

| Claimed Shelf Life in CPR | Minimum Remaining Shelf Life Upon Delivery |
|---------------------------|---|
| 60 months | 42 – 60 months |
| 48 months | 34 – 48 months |
| 36 months | 30-36 months |
| 24 months | 18 – 24 months |
| 18 months | 12-18 months |
| 12 months | 12 months |

- 2. The CPR must be valid for the entire period of the award. If the CPR is about to expire, the supplier must have submitted a copy of an application of renewal to the FDA at least 3 months before the expiry date (a copy of the expiring CPR which is stamped with an "extension of validity" shall be submitted as proof).
- 3. The Pharmacist-in-charge of inspection and acceptance of pharmaceutical products and devices shall conduct random sampling of the products delivered for batch testing.
 - 3.1 The samples collected shall be submitted to FDA for test analysis. The Pharmacist shall determine the kind of test(s) to be done based on the physical inspection done. (Annex A)
 - 3.2 The supplier shall replace (same batch) or pay the cost of the samples collected for testing.
 - 3.3 The supplier shall pay the cost of testing of the products collected.
- 4. The supplier shall be provided with a copy of the result of tests analysis done on their products.
- 5. The supplier shall submit the batch notification for antibiotic products and batch certificate for vaccines issued by the FDA upon delivery.

- 6. The performance of the suppliers shall be monitored based on the following Key Performance Indicators:
 - 6.1 Suppliers meet quality and service standards specified in the Terms of Reference (TOR)/Purchase Order (PO)/Contract
 - 6.2 Timeliness of delivery
 - 6.3 Completeness of quantity delivered
 - 6.4 Zero defects of products
 - 6.5 Relevant additional services provided (e.g. disposal, recall)

CONFORME :

Authorized Signatory Signature over printed name

ANNEX A

Minimum Number of Sample Units Required for Each Test Analysis (FDA Circular No. 2014-014 dated 16 March 2014)

PHARMACEUTICAL PRODUCTS

a. Microbiological Tests

| Sample Type | Test Parameter | Number of |
|-------------------------|--|----------------------|
| | | Sample Units |
| Nonaqueous/aqueous | Total Aerobic Microbial Count | Minimum of 2 |
| preparation for oral | Total Combined Yeast & Mold Count | commercial |
| use | •Absence of Escherichia coli in 1g or mL | presentations with a |
| Rectal Use | Total Aerobic Microbial count | total net weight or |
| | •Total Combined Yeast & Mold Count | volume of not less |
| Oromucosal/Gingival/ | Total Aerobic Microbial Count | than 50g or mL |
| Cutaneous/Nasal/Auri | •Total Combined Yeast & Mold Count | |
| cular use | •Absence of Staphylococcus aureus in 1g or mL | |
| | •Absence of Pseudomonas Aeroginosa in 1 g or mL | |
| Inhalation use (special | Total Aerobic Microbial Count | |
| requirements apply to | •Total Combined Yeast & Mold Count | |
| liquid preparations for | •Absence of Staphylococcus aureus in 1g or mL | |
| nebulization) | •Absence of bile-tolerant Gram-negative bacteria in 1 g or | |
| | mL | |

b. Biological Tests

| Sample Type | Test Parameter | Number of Sample Units |
|--|--------------------------|---------------------------|
| Liquid Preparations 1mL to 100mL More than 100mL | Bacterial endotoxin test | 20 bottles 6 bottels |
| 1mL to 100mL 500 to 1000mL | • Sterility Test | 20 bottles 6 bottles |
| Solid Preparations | Sterility Test | 20 units |

c. Physico-chemical Tests

| Sample Type | Test Parameter | Number of |
|---------------------|----------------------------|---------------------|
| | | Sample Units |
| Tablet/Capsule | Assay/Potency | 60 tablets/capsules |
| | Dissolution | 50 tablets/capsules |
| | Uniformity of Dosage Units | 40 tablets/capsules |
| | Identification Test | 20 tablets/capsules |
| | Disintegration | 20 tablets/capsules |
| | Tablet hardness | 10 tablets/capsules |
| Granules/Powder for | Assay and Minimum Fill | 10 bottles |
| Suspension/Syrup | • pH | 2 bottles |
| | Identification Test | 3 bottles |
| Injectables | Assay/Potency | 20 vials/ampules |
| (1mL to 2mL) | • pH | 10 vials/ampules |
| Injectables | | 20 vials/ampules |

| (5mL to 10mL) | | 5 vials/ampules |
|--------------------|---------------|---------------------|
| Injectables | | 10 vials/ampules |
| (20mL to 100mL) | | 2 vials/ampules |
| Ointment/Cream/Gel | Assay/Potency | 10 tubes |
| Aerosol | | 10 pressurized cans |
| Suppositories | | 30 pieces |

PHARMACEUTICAL CONTAINERS

| Sample Type | Test Parameter | Number of |
|-----------------------|---------------------|--------------|
| 1 71 | | Sample Units |
| Plastic container for | Nonvolatile residue | 2000-000 |
| suspension/syrup, | Residue on Ignition | |
| oral preparations | • Lead | |
| a. 10 mL | Buffering Capacity | 120 pcs |
| b. 30 to 60 mL | | 60 pcs |
| c. 60 to 100mL | | 40 pcs |
| d. 250 mL | | 20 pcs |
| e. 500 to | | 10 pcs |
| 1000mL | | |
| Plastic bottles/IV | Sterility Test | |
| infusion | | |
| a. 100mL | | 15 pcs |
| b. 250mL | | 10 pcs |
| c. 500 to | | 6 pcs |
| 1000mL | | |
| Polyampules | | |
| a. 1 to 2 mL | | 300 pcs |
| b. 3 to 5 mL | | 250 pcs |
| c. 6 to 10 mL | | 200 pcs |
| Vials | | |
| a. 10 mL | | 120 pcs |
| b. 20 to 25 mL | | 60 pcs |
| c. 30 to 50 mL | | 30 pcs |
| Caps (Diameter) | | |
| a. <u><</u> 0.5 cm | | 800 pcs |
| b. Between 1 & | | 48 pcs |
| 2.5 cm | | |
| c. $> 2.5 \text{ cm}$ | | 30 pcs |

DEVICES

| Sample Type | Test Parameter | Number of |
|-----------------|--------------------------|--------------|
| | | Sample Units |
| Medical Devices | Bacterial endotoxin test | 20 units |
| | Sterility Test | 20 units |

CONFORME :

Authorized Signatory Signature over printed name

Quezon Avenue, Quezon City

TERMS OF REFERENCE CY 2021

70% ETHYL ALCOHOL

- 1. The winning bidder for 70 % ethyl alcohol shall have a one-year contract in supplying the requirements of PCMC.
- 2. The supplier for 70% ethyl alcohol shall provide alcohol dispensers to all identified wards, clinic areas, and units (see attached) within the contract period.

The supplier shall install the alcohol dispensers in all the identified units/clinical (attached list) areas in the hospital.

The supplier shall also provide the stand/wall cabinet of the alcohol dispenser.

3. The supplier shall be responsible for the monthly preventive maintenance of the alcohol dispensers installed with no additional cost to PCMC. This shall include:

Repair of the dispenser

Replacement of defective parts (if applicable)

Replacement of the dispenser if found defective and beyond repair

- 4. The supplier shall accommodate emergency calls during office hours in the event that any of the dispensers in the hospital is non-operational.
- 5. The supplier shall be responsible in collecting and disposing of the empty bottles of alcohol.

CONFORME :

Authorized Signatory Signature over printed name

LIST OF WARDS/ CLINICS/ UNITS TO BE PROVIDED WITH ALCOHOL DISPENSER:

| Ward/ Clinic/Unit | Quantity |
|---------------------------|----------|
| Emergency Room | 10 |
| ER Triage | 15 |
| Cancer & Hematology WARD | 15 |
| OPD Cancer and Hematology | 15 |
| CNS | 9 |
| 1B subspecialty/surgery | 5 |
| New Born Surgery | 10 |
| Ward 2A | 18 |
| Ward 2B | 25 |
| Ward 2D | 15 |
| Ward 19 | 25 |
| Pathology | 10 |
| Regular ICU | 30 |
| NICU | 25 |
| SICU | 16 |
| Operating Room | 20 |
| Perinatal | 10 |
| Post partum | 10 |
| OPD/Triage | 40 |
| Rehabilitation Medicine | 15 |
| Pharmacy | 10 |
| Sterilization Room | 5 |
| Radiology | 15 |
| Employee's Clinic | 2 |
| Diagnostic Area | 10 |
| Heart Institute | 4 |
| Peritoneal Dialysis Unit | 6 |
| Hemodialysis Unit | 25 |

CONFORME :

Authorized Signatory Signature over printed name